Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지

A Case of Acute Cholestatic Hepatitis Associated with Orlistat

Orlistat 복용과 관련된 급성 담즙정체성 간염 유발 증례

Kim, Doh-Hyun;Lee, Eun-Hee;Hwang, Jae-Chul;Jeung, Jai-Hak;Kim, Do-Hyun;Cheong, Jae-Youn;Kim, Won-Seok;Cho, Sung-Won;Kim, Young-Bae
김도현;이은희;황재철;정재학;김도현;정재연;김원석;조성원;김영배

  • Published : 20020000
⟨ Previous Next ⟩

Abstract

Orlistat(Xenical$^{\circledR}$, Roche) is considered a safe and effective drug to treat obesity by reduced absorption of 30% digested fat. To date, no serious adverse effects affecting the liver have been published except a case of subacute hepatic failure leading to liver transplantation in a young women with moderate obesity treated with orlistat. We report a case of acute cholestatic hepatitis in a young woman with moderate obesity treated with orlistat: a 33-year-old female admitted for the evaluation of jaundice. Abdominal ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle biopsy of liver were performed. Microscopic findings of the liver biopsy specimen were compatible with acute cholestatic hepatitis. After steroid therapy, liver function was improved.

Keywords

References

  1. Hvizdos KM, Markham A. Orlistat: A review of its use in the Management of Obesity. Drugs 1999;58(4):743-760 https://doi.org/10.2165/00003495-199958040-00015
  2. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA 1999;281(3):235-242 https://doi.org/10.1001/jama.281.3.235
  3. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-1294 https://doi.org/10.2337/diacare.21.8.1288
  4. Crenier L, Sternon J. Orlistat(Xenical). Rev Med Brux, 1999 Jun;20(3):159-63
  5. Wong NN, Cheng-Lai A. Orlistat. Heart Dis, 2000 Mar- Apr;2(2):174-81
  6. Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Haeussler J, Guerciolini R, Showalter R, Everson GT. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol, 2001 Jun;96(6): 1888-94 https://doi.org/10.1111/j.1572-0241.2001.03783.x
  7. Montero JL, Muntane J, Fraga E, Delgado M, Costan G, Serrano M, Padillo J, de la Mata M, Mino G. Orlistat associated subacute hepatic failure. J Hepatol, 2001 Jan;34(1):173
  8. Barbare JC, Imbert A, Benkirane A. Hepatotoxicity of medications. Presse Med, 2001 Apr 14;30(14):673-6
  9. Guruprasad P. Aithal, Michael D. Rawling, Christopher P. Day. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol, 2000;33:949-952